GöteborgBIO
Friday 3 September, 2010
Home
Healthy figures for 2009
Many Swedish life-science companies are reporting positive earnings for the first quarter of 2009, including Biovitrum, Vitrolife, Q-Med, Aerocrine and CellaVivision, interim reports for the first quarter show.
The Göteborg-based biotechnology company Vitrolife, with products in the fields of fertility treatment, transplantation and stem-cell cultivation, is also reporting positive figures. Sales rose by 22 per cent to SEK 71.8 million, and March was the firm´s best month ever. Since the start of the year the company has opened a sales office in China and launched a marketing organisation in Japan. It has also had its needle Swemed Sense, for the removal of human eggs in in-vitro fertilisation, approved by the American Food and Drug Administration (FDA).

The pharmaceutical company Biovitrum increased its net revenues by 78 per cent, to SEK 355 million, in comparison with the previous year.

The Uppsala-based company Q-Med´s revenues from product sales and royalties rose by 17 per cent to SEK 339 million. Since the first quarter, Q-Med has sold its American subsidiary Q-Med Scandinavia Inc to Oceana Therapeutics and will now focus more on the area of aesthetics.

The medical devices company Aerocrine, which develops and sells equipment to measure exhaled nitric oxide, increased its net sales by 29 per cent to SEK 26.9 million.

The Lund-based company CellaVision increased its net sales by 19 per cent to SEK 22 million. The company´s Japanese subsidiary received its first order in April, and in the same month CellaVision was nominated for the SwedenBIO Award for the progress it made in 2008.

Felicia Lindberg / Chemicalnet.se

Updated: 2010-08-25
Print this page
Print this page
GöteborgBIO | Address: Medicinaregatan 8a | SE-413 46 Göteborg | Sweden | Fax: +46 31-41 97 00